# Lung Cancer in Women Treated With Anti-oestrogens anD Inhibitors of EGFR

> **NCT01556191** · PHASE2 · COMPLETED · sponsor: **Intergroupe Francophone de Cancerologie Thoracique** · enrollment: 379 (actual)

## Conditions studied

- Stage IV Lung Cancer

## Interventions

- **DRUG:** Gefitinib
- **DRUG:** Fulvestrant
- **DRUG:** Erlotinib

## Key facts

- **NCT ID:** NCT01556191
- **Lead sponsor:** Intergroupe Francophone de Cancerologie Thoracique
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-05-15
- **Primary completion:** 2018-05-15
- **Final completion:** 2020-06-17
- **Target enrollment:** 379 (ACTUAL)
- **Last updated:** 2021-01-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01556191

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01556191, "Lung Cancer in Women Treated With Anti-oestrogens anD Inhibitors of EGFR". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01556191. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*